Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval

By: MarketWatch
Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.
Related Stocks:
89bio, Inc. - Common Stock Eli Lilly GENFIT S.A. - American Depositary Shares Intercept Pharmaceuticals, Inc. - Common Stock Madrigal Pharmaceuticals, Inc. - Common Stock NGM Biopharmaceuticals, Inc. - Common Stock Terns Pharmaceuticals, Inc. - Common Stock Viking Therapeutics, Inc. - Common Stock
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.